Stereotactic ablative radiotherapy for unresectable inferior vena cava tumor thrombus in a patient with renal cell carcinoma: a case report
Purpose Treatment options for renal cell carcinoma (RCC) with inferior vena cava tumor thrombus (IVC-TT) are limited and carry substantial risks. Currently, there are no standard treatment options in the setting of recurrent or unresectable RCC with IVC-TT. Methods We report our experience of treati...
Gespeichert in:
| Veröffentlicht in: | Strahlentherapie und Onkologie 2023-04, Vol.199 (4), p.420-424 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 424 |
|---|---|
| container_issue | 4 |
| container_start_page | 420 |
| container_title | Strahlentherapie und Onkologie |
| container_volume | 199 |
| creator | Castelnau-Marchand, Pauline Scher, Nathaniel Bollet, Marc Chargari, Cyrus Toledano, Alain |
| description | Purpose
Treatment options for renal cell carcinoma (RCC) with inferior vena cava tumor thrombus (IVC-TT) are limited and carry substantial risks. Currently, there are no standard treatment options in the setting of recurrent or unresectable RCC with IVC-TT.
Methods
We report our experience of treating an IVC-TT RCC patient with stereotactic body radiation therapy (SBRT).
Results
This 62-year-old gentleman presented renal cell carcinoma with IVC-TT and liver metastases. Initial treatment consisted of radical nephrectomy and thrombectomy followed by continuous sunitinib. At 3 months, he developed an unresectable IVC-TT recurrence. A fiducial marker was implanted into the IVC-TT by catheterization. New biopsies were performed at the same time, demonstrating a recurrence of the RCC. SBRT consisted of 5 fractions of 7 Gy to the IVC-TT with excellent initial tolerance. He subsequently received anti-PD1 therapy (nivolumab). At 4 years follow-up, he is doing well with no IVC-TT recurrence and no late toxicity.
Conclusion
SBRT appears to be a feasible and safe treatment for IVC-TT secondary to RCC in patients who are not candidates for surgery. |
| doi_str_mv | 10.1007/s00066-023-02054-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_04071192v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2789558146</sourcerecordid><originalsourceid>FETCH-LOGICAL-c409t-3f181ee626d9afe52e59c172d8829c7571c5fb7bfaa5be57f028312e6c66fa233</originalsourceid><addsrcrecordid>eNp9kcFu1DAQhiMEokvhBTggS1zgELCd2I65VRVQpJU4ABI3a-Ids66SeLGdrfoQvAPPwpPhNKVIHDh4LM98849Hf1U9ZfQVo1S9TpRSKWvKm3KoaGt6r9qwttE11frr_WpDmdK1YqI7qR6ldEkpk61uH1YnjewkZ6LdVD8-ZYwYMtjsLYF-gOyPSCLsfMh7jHC4Ji5EMk8RE9pcCCR-chh9yR5xAmLhCCTPY3nnfQxjP6dCEPj181DEcMrkyuc9iYUdiMWhBIjWT2GENwtlIZWBeAgxP64eOBgSPrm9T6sv795-Pr-otx_ffzg_29a2pTrXjWMdQ5Rc7jQ4FByFtkzxXddxbZVQzArXq94BiB6FcpR3DeMorZQOeNOcVi9X3T0M5hD9CPHaBPDm4mxrlhxtqWJM8yMr7IuVPcTwfcaUzejTsgZMGOZkuOqYZJo2sqDP_0EvwxzL2jeUFqJj7ULxlbIxpBTR3f2AUbMYa1ZjTTHW3BhraGl6dis99yPu7lr-OFmAZgVSKU3fMP6d_R_Z39-qsSU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2789558146</pqid></control><display><type>article</type><title>Stereotactic ablative radiotherapy for unresectable inferior vena cava tumor thrombus in a patient with renal cell carcinoma: a case report</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Castelnau-Marchand, Pauline ; Scher, Nathaniel ; Bollet, Marc ; Chargari, Cyrus ; Toledano, Alain</creator><creatorcontrib>Castelnau-Marchand, Pauline ; Scher, Nathaniel ; Bollet, Marc ; Chargari, Cyrus ; Toledano, Alain</creatorcontrib><description>Purpose
Treatment options for renal cell carcinoma (RCC) with inferior vena cava tumor thrombus (IVC-TT) are limited and carry substantial risks. Currently, there are no standard treatment options in the setting of recurrent or unresectable RCC with IVC-TT.
Methods
We report our experience of treating an IVC-TT RCC patient with stereotactic body radiation therapy (SBRT).
Results
This 62-year-old gentleman presented renal cell carcinoma with IVC-TT and liver metastases. Initial treatment consisted of radical nephrectomy and thrombectomy followed by continuous sunitinib. At 3 months, he developed an unresectable IVC-TT recurrence. A fiducial marker was implanted into the IVC-TT by catheterization. New biopsies were performed at the same time, demonstrating a recurrence of the RCC. SBRT consisted of 5 fractions of 7 Gy to the IVC-TT with excellent initial tolerance. He subsequently received anti-PD1 therapy (nivolumab). At 4 years follow-up, he is doing well with no IVC-TT recurrence and no late toxicity.
Conclusion
SBRT appears to be a feasible and safe treatment for IVC-TT secondary to RCC in patients who are not candidates for surgery.</description><identifier>ISSN: 0179-7158</identifier><identifier>EISSN: 1439-099X</identifier><identifier>DOI: 10.1007/s00066-023-02054-0</identifier><identifier>PMID: 36862154</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Ablation ; Bioengineering ; Blood clots ; Carcinoma, Renal Cell - pathology ; Carcinoma, Renal Cell - radiotherapy ; Case reports ; Case Study ; Human health and pathology ; Humans ; Imaging ; Kidney cancer ; Kidney Neoplasms - pathology ; Kidney Neoplasms - radiotherapy ; Life Sciences ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Nephrectomy - adverse effects ; Oncology ; Radiation therapy ; Radiosurgery - adverse effects ; Radiotherapy ; Retrospective Studies ; Surgery ; Toxicity ; Tumors ; Vena Cava, Inferior - pathology ; Vena Cava, Inferior - surgery ; Venous Thrombosis - complications ; Venous Thrombosis - radiotherapy</subject><ispartof>Strahlentherapie und Onkologie, 2023-04, Vol.199 (4), p.420-424</ispartof><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany 2023</rights><rights>2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.</rights><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany 2023.</rights><rights>Copyright</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c409t-3f181ee626d9afe52e59c172d8829c7571c5fb7bfaa5be57f028312e6c66fa233</citedby><cites>FETCH-LOGICAL-c409t-3f181ee626d9afe52e59c172d8829c7571c5fb7bfaa5be57f028312e6c66fa233</cites><orcidid>0000-0003-1221-4076</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00066-023-02054-0$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00066-023-02054-0$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,778,782,883,27907,27908,41471,42540,51302</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36862154$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://cnam.hal.science/hal-04071192$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Castelnau-Marchand, Pauline</creatorcontrib><creatorcontrib>Scher, Nathaniel</creatorcontrib><creatorcontrib>Bollet, Marc</creatorcontrib><creatorcontrib>Chargari, Cyrus</creatorcontrib><creatorcontrib>Toledano, Alain</creatorcontrib><title>Stereotactic ablative radiotherapy for unresectable inferior vena cava tumor thrombus in a patient with renal cell carcinoma: a case report</title><title>Strahlentherapie und Onkologie</title><addtitle>Strahlenther Onkol</addtitle><addtitle>Strahlenther Onkol</addtitle><description>Purpose
Treatment options for renal cell carcinoma (RCC) with inferior vena cava tumor thrombus (IVC-TT) are limited and carry substantial risks. Currently, there are no standard treatment options in the setting of recurrent or unresectable RCC with IVC-TT.
Methods
We report our experience of treating an IVC-TT RCC patient with stereotactic body radiation therapy (SBRT).
Results
This 62-year-old gentleman presented renal cell carcinoma with IVC-TT and liver metastases. Initial treatment consisted of radical nephrectomy and thrombectomy followed by continuous sunitinib. At 3 months, he developed an unresectable IVC-TT recurrence. A fiducial marker was implanted into the IVC-TT by catheterization. New biopsies were performed at the same time, demonstrating a recurrence of the RCC. SBRT consisted of 5 fractions of 7 Gy to the IVC-TT with excellent initial tolerance. He subsequently received anti-PD1 therapy (nivolumab). At 4 years follow-up, he is doing well with no IVC-TT recurrence and no late toxicity.
Conclusion
SBRT appears to be a feasible and safe treatment for IVC-TT secondary to RCC in patients who are not candidates for surgery.</description><subject>Ablation</subject><subject>Bioengineering</subject><subject>Blood clots</subject><subject>Carcinoma, Renal Cell - pathology</subject><subject>Carcinoma, Renal Cell - radiotherapy</subject><subject>Case reports</subject><subject>Case Study</subject><subject>Human health and pathology</subject><subject>Humans</subject><subject>Imaging</subject><subject>Kidney cancer</subject><subject>Kidney Neoplasms - pathology</subject><subject>Kidney Neoplasms - radiotherapy</subject><subject>Life Sciences</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Nephrectomy - adverse effects</subject><subject>Oncology</subject><subject>Radiation therapy</subject><subject>Radiosurgery - adverse effects</subject><subject>Radiotherapy</subject><subject>Retrospective Studies</subject><subject>Surgery</subject><subject>Toxicity</subject><subject>Tumors</subject><subject>Vena Cava, Inferior - pathology</subject><subject>Vena Cava, Inferior - surgery</subject><subject>Venous Thrombosis - complications</subject><subject>Venous Thrombosis - radiotherapy</subject><issn>0179-7158</issn><issn>1439-099X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNp9kcFu1DAQhiMEokvhBTggS1zgELCd2I65VRVQpJU4ABI3a-Ids66SeLGdrfoQvAPPwpPhNKVIHDh4LM98849Hf1U9ZfQVo1S9TpRSKWvKm3KoaGt6r9qwttE11frr_WpDmdK1YqI7qR6ldEkpk61uH1YnjewkZ6LdVD8-ZYwYMtjsLYF-gOyPSCLsfMh7jHC4Ji5EMk8RE9pcCCR-chh9yR5xAmLhCCTPY3nnfQxjP6dCEPj181DEcMrkyuc9iYUdiMWhBIjWT2GENwtlIZWBeAgxP64eOBgSPrm9T6sv795-Pr-otx_ffzg_29a2pTrXjWMdQ5Rc7jQ4FByFtkzxXddxbZVQzArXq94BiB6FcpR3DeMorZQOeNOcVi9X3T0M5hD9CPHaBPDm4mxrlhxtqWJM8yMr7IuVPcTwfcaUzejTsgZMGOZkuOqYZJo2sqDP_0EvwxzL2jeUFqJj7ULxlbIxpBTR3f2AUbMYa1ZjTTHW3BhraGl6dis99yPu7lr-OFmAZgVSKU3fMP6d_R_Z39-qsSU</recordid><startdate>20230401</startdate><enddate>20230401</enddate><creator>Castelnau-Marchand, Pauline</creator><creator>Scher, Nathaniel</creator><creator>Bollet, Marc</creator><creator>Chargari, Cyrus</creator><creator>Toledano, Alain</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><general>Springer Verlag (Germany)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FG</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0003-1221-4076</orcidid></search><sort><creationdate>20230401</creationdate><title>Stereotactic ablative radiotherapy for unresectable inferior vena cava tumor thrombus in a patient with renal cell carcinoma: a case report</title><author>Castelnau-Marchand, Pauline ; Scher, Nathaniel ; Bollet, Marc ; Chargari, Cyrus ; Toledano, Alain</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c409t-3f181ee626d9afe52e59c172d8829c7571c5fb7bfaa5be57f028312e6c66fa233</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Ablation</topic><topic>Bioengineering</topic><topic>Blood clots</topic><topic>Carcinoma, Renal Cell - pathology</topic><topic>Carcinoma, Renal Cell - radiotherapy</topic><topic>Case reports</topic><topic>Case Study</topic><topic>Human health and pathology</topic><topic>Humans</topic><topic>Imaging</topic><topic>Kidney cancer</topic><topic>Kidney Neoplasms - pathology</topic><topic>Kidney Neoplasms - radiotherapy</topic><topic>Life Sciences</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Nephrectomy - adverse effects</topic><topic>Oncology</topic><topic>Radiation therapy</topic><topic>Radiosurgery - adverse effects</topic><topic>Radiotherapy</topic><topic>Retrospective Studies</topic><topic>Surgery</topic><topic>Toxicity</topic><topic>Tumors</topic><topic>Vena Cava, Inferior - pathology</topic><topic>Vena Cava, Inferior - surgery</topic><topic>Venous Thrombosis - complications</topic><topic>Venous Thrombosis - radiotherapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Castelnau-Marchand, Pauline</creatorcontrib><creatorcontrib>Scher, Nathaniel</creatorcontrib><creatorcontrib>Bollet, Marc</creatorcontrib><creatorcontrib>Chargari, Cyrus</creatorcontrib><creatorcontrib>Toledano, Alain</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection (ProQuest)</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Strahlentherapie und Onkologie</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Castelnau-Marchand, Pauline</au><au>Scher, Nathaniel</au><au>Bollet, Marc</au><au>Chargari, Cyrus</au><au>Toledano, Alain</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Stereotactic ablative radiotherapy for unresectable inferior vena cava tumor thrombus in a patient with renal cell carcinoma: a case report</atitle><jtitle>Strahlentherapie und Onkologie</jtitle><stitle>Strahlenther Onkol</stitle><addtitle>Strahlenther Onkol</addtitle><date>2023-04-01</date><risdate>2023</risdate><volume>199</volume><issue>4</issue><spage>420</spage><epage>424</epage><pages>420-424</pages><issn>0179-7158</issn><eissn>1439-099X</eissn><abstract>Purpose
Treatment options for renal cell carcinoma (RCC) with inferior vena cava tumor thrombus (IVC-TT) are limited and carry substantial risks. Currently, there are no standard treatment options in the setting of recurrent or unresectable RCC with IVC-TT.
Methods
We report our experience of treating an IVC-TT RCC patient with stereotactic body radiation therapy (SBRT).
Results
This 62-year-old gentleman presented renal cell carcinoma with IVC-TT and liver metastases. Initial treatment consisted of radical nephrectomy and thrombectomy followed by continuous sunitinib. At 3 months, he developed an unresectable IVC-TT recurrence. A fiducial marker was implanted into the IVC-TT by catheterization. New biopsies were performed at the same time, demonstrating a recurrence of the RCC. SBRT consisted of 5 fractions of 7 Gy to the IVC-TT with excellent initial tolerance. He subsequently received anti-PD1 therapy (nivolumab). At 4 years follow-up, he is doing well with no IVC-TT recurrence and no late toxicity.
Conclusion
SBRT appears to be a feasible and safe treatment for IVC-TT secondary to RCC in patients who are not candidates for surgery.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>36862154</pmid><doi>10.1007/s00066-023-02054-0</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0003-1221-4076</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0179-7158 |
| ispartof | Strahlentherapie und Onkologie, 2023-04, Vol.199 (4), p.420-424 |
| issn | 0179-7158 1439-099X |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_04071192v1 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Ablation Bioengineering Blood clots Carcinoma, Renal Cell - pathology Carcinoma, Renal Cell - radiotherapy Case reports Case Study Human health and pathology Humans Imaging Kidney cancer Kidney Neoplasms - pathology Kidney Neoplasms - radiotherapy Life Sciences Male Medicine Medicine & Public Health Middle Aged Nephrectomy - adverse effects Oncology Radiation therapy Radiosurgery - adverse effects Radiotherapy Retrospective Studies Surgery Toxicity Tumors Vena Cava, Inferior - pathology Vena Cava, Inferior - surgery Venous Thrombosis - complications Venous Thrombosis - radiotherapy |
| title | Stereotactic ablative radiotherapy for unresectable inferior vena cava tumor thrombus in a patient with renal cell carcinoma: a case report |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T12%3A55%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Stereotactic%20ablative%20radiotherapy%20for%20unresectable%20inferior%20vena%20cava%20tumor%20thrombus%20in%20a%C2%A0patient%20with%20renal%20cell%20carcinoma:%20a%C2%A0case%20report&rft.jtitle=Strahlentherapie%20und%20Onkologie&rft.au=Castelnau-Marchand,%20Pauline&rft.date=2023-04-01&rft.volume=199&rft.issue=4&rft.spage=420&rft.epage=424&rft.pages=420-424&rft.issn=0179-7158&rft.eissn=1439-099X&rft_id=info:doi/10.1007/s00066-023-02054-0&rft_dat=%3Cproquest_hal_p%3E2789558146%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2789558146&rft_id=info:pmid/36862154&rfr_iscdi=true |